99 filings
Page 4 of 5
UPLOAD
6j1ti99o
30 Sep 22
Letter from SEC
12:00am
8-K
l4qdxmylb9wvdjjatj6l
19 Sep 22
Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock
8:10am
8-K
zab t3gyh1
15 Aug 22
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
4:32pm
8-K
iahk wb0lt7nu
29 Jun 22
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
8:30am
8-K
o0nwkqp wcf8yeku
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
zjrkr2z9 4d
12 May 22
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
4:09pm
8-K
deyvrjsqis74s9d zm
9 May 22
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
8:07am
DEFA14A
1fy6e2ia
27 Apr 22
Additional proxy soliciting materials
4:16pm
DEF 14A
lpr2br
27 Apr 22
Definitive proxy
4:10pm
10-K
njpbtvdh7siiyx8
23 Mar 22
Annual report
5:49pm
8-K
e4odtc3 iexv8b7sa
23 Mar 22
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
8:15am
8-K
in0j0p
15 Mar 22
Regulation FD Disclosure
6:07am
8-K
1jnoyg1g4hx5d
30 Nov 21
Regulation FD Disclosure
4:06pm
10-Q
plqpaxheleiulsfps
18 Nov 21
Quarterly report
12:00am
8-K
6m1y1z rtfthes8
17 Nov 21
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
4:23pm
8-K
png6ne93qtq2gheray
25 Oct 21
Ventyx Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
5:09pm
S-8
nk5ehlrn
21 Oct 21
Registration of securities for employees
5:30pm